Filed by Corgentech Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: AlgoRx Pharmaceuticals, Inc. Commission File No. of Subject Company: 000-51146 | ||||
*** *** *** The following is a slide presentation used at investor meetings on October 6 and 7, 2005. |
Creating a Late-Stage Company Focused on Pain Management and Inflammation
October 6-7, 2005
FORWARD LOOKING STATEMENTS
This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this presentation include, without limitation, forecasts of product development, FDA filings, benefits of the proposed merger, and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied in this presentation. Such risk factors include, among others: difficulties encountered in integrating merged businesses; uncertainties as to the timing of the merger; approval of the transaction by the stockholders of the companies; the satisfaction of closing conditions to the transaction, including the receipt of regulatory approvals; whether certain market segments grow as anticipated; the competitive environment in the biotechnology industry; and whether the companies can successfully develop new products and the degree to which these gain market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this presentation. Additional information concerning these and other risk factors is contained in Corgentech’s Form 10-K/A for the year ended December 31, 2004 and most recently filed Form10-Q.
Corgentech and AlgoRx undertake no obligation and do not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. All forward-looking statements are qualified in their entirety by this cautionary statement.
2 |
|
FORWARD LOOKING STATEMENTS (2)
Additional Information and Where to Find It
Corgentech Inc. intends to file a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. intend to file a related joint proxy statement/prospectus, in connection with the merger transaction involving Corgentech and AlgoRx. Investors and security holders are urged to read the registration statement on Form S-4 and the related joint proxy/prospectus when they become available because they will contain important information about the merger transaction. Investors and security holders may obtain free copies of these documents (when they are available) and other documents filed with the SEC at the SEC’s web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by contacting Corgentech Investor Relations at the email address: investors@corgentech.com.
Corgentech, AlgoRx and their directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Corgentech and AlgoRx in connection with the merger transaction. Information regarding the special interests of these directors and executive officers in the merger transaction will be included in the joint proxy statement/prospectus of AlgoRx and Corgentech described above. Additional information regarding the directors and executive officers of Corgentech is also included in Corgentech’s proxy statement for its 2005 Annual Meeting of Stockholders, which was filed with the SEC on April 27, 2005. This document is available free of charge at the SEC’s web site at www.sec.gov and from Investor Relations at Corgentech as described above.
3 |
|
CREATING LATE-STAGE COMPANY
Four product development programs focused on significant clinical problems with attractive market potential
Each drug has unique mechanism of action offering risk diversification
Each drug has potential for approval in multiple indications
Each drug can be commercialized with specialty sales force
All discovery and development programs 100% owned
Phase 3 program ALGRX 3268 for the treatment of venipuncture
Statistically significantly less pain in first Phase 3 trial
Second Phase 3 trial data expected within two months
Expect to file NDA in 1H06
Expect product approval in 1H07
Development and commercial expertise in critical areas
Marketing, commercialization, regulatory affairs, manufacturing and clinical trials management
Financial strength and flexibility
4 |
|
AGENDA
Terms of merger agreement Product pipeline of combined company ALGRX 3268: positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense
5 |
|
TERMS OF MERGER AGREEMENT
Stock Transaction
At close of merger, Corgentech would issue sufficient shares such that AlgoRx shareholders would own, in a tax-free exchange, 62% and Corgentech shareholders would own 38% of the combined company, respectively
Combined management team will work to integrate the companies and to identify synergies and redundancies
Corgentech and AlgoRx currently employ ~95 people total
Board and Management
Richard Brewer, Dr. Charles Cohen, Thomas Colligan, Carter Eckert, Dr. Rodney Ferguson, John McLaughlin, Dr. Arnold Oronsky and Dr. Michael Powell ?A ninth board member to be identified and added soon after deal approval
Management
John McLaughlin as CEO
Dr. Ronald Burch, current AlgoRx CEO, to serve as VP of Development ?Richard Powers to remain as CFO
James Huang newly elected as president with responsibility for commercial and other operations Secaucus and South San Francisco facilities to remain open Headquarters: South San Francisco 6
AGENDA
Terms of merger agreement Product pipeline of combined company ALGRX 3268: positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense
7 |
|
PRODUCT PIPELINE
PRECLINICAL PHASE 1 PHASE 2 PHASE 3
ALGRX 3268
Pre-procedural analgesia (003)
Pre-procedural analgesia (004)
ALGRX 4975 *
Post-surgical pain
Morton’s neuroma
Tendonitis
NF-kB Decoy *
Atopic dermatitis (eczema)
ALGRX 1207 *
Cutaneous neuropathic pain
* |
| Does not reflect comprehensive list of trials currently underway |
8 |
|
ALGRX 3268-
TOPICAL LOCAL ANESTHESIA
Indication
Reduction of pain associated with venipunctures and intravenous line placements
Two Phase 3 trials being conducted Key desirable product attributes
Sterile, pre-filled, needle-free disposable delivery system (Powderject®) Rapid onset of action
Within 1 minute with duration of about 10 minutes
No vasoconstriction with good dermal tolerability Ease of use with no dressings
9
ALGRX 3268
Reduction in Pain from Venipuncture after Administration
EMLA
Package Insert for EMLA
VAS, mm
10 0 -10 -20 -30
3 |
|
60
Time after administration, minutes
ALGRX 3268
Data from Phase 1 trial in 272 adults
VAS, mm
10 0 -10 -20 -30
1 |
|
3 |
|
5 |
|
Time after administration, minutes
ALGRX 3268 has an onset within one minute, whereas EMLA is labeled for a pretreatment period of at least one hour
10
PHASE 1 TRIAL: ANTECUBITAL FOSSA
Design
U.S. single center, randomized, double-blind, placebo-controlled, 2-way cross-over, dose ranging Three configurations of ALGRX 3268 tested
Number of subjects
272 subjects enrolled for 240 evaluable subjects
Population
Normal healthy subjects of either gender aged 18 and above
Objectives
Identify an optimal configuration (dose, pressure) for future studies at the antecubital fossa based on efficacy and tolerability
Criteria for evaluation
Efficacy: Reduction in pain on venipuncture (performed at 8 different time points) following ALGRX 3268 or placebo, using 10 cm VAS scale
Safety: skin evaluations for erythema, edema/induration, pruritus and hemorrhage/petechia and adverse events
11
PHASE I RESULTS: ANTECUBITAL FOSSA
Efficacy endpoint
For all 3 device configurations, for all time points combined, reductions in pain were statistically significantly superior to placebo treatment (with most profound anesthesia from 1 to 5 minutes)
0.25mg/20bar vs. 20bar placebo n=80 p=0.0217 ?0.50mg/20bar vs. 20bar placebo n=80 p=0.0129 0.50mg/40bar vs. 40bar placebo n=80 p=0.0002
Safety endpoint
Either 0.25mg or 0.5mg lidocaine and lower gas pressure were very well tolerated
The higher pressure of 40 bar had higher degrees of erythema and hemorrhage/petechia
Conclusion
Based on efficacy and tolerability, recommendation is made to pursue development for the anticubital fossa of 0.50mg/20bar configuration
12
PHASE 1 TRIAL: BACK OF HAND
Design
U.S. single center, randomized, double-blind, placebo-controlled, 2-way cross-over, dose ranging Two configurations of ALGRX 3268 tested
Number of subjects
183 subjects enrolled for 159 evaluable subjects
Population
Normal healthy subjects of either gender aged 18 and above
Objectives
Identify an optimal configuration (dose, pressure) for future studies at the back of hand based on efficacy and tolerability
Criteria for evaluation
Efficacy: Reduction in pain on venipuncture (performed at 4 different time points) following ALGRX 3268 or placebo using 10 cm VAS scale
Safety: skin evaluations for erythema, edema/induration, pruritus and hemorrhage/petechia and adverse events
13
PHASE I RESULTS: BACK OF HAND
Efficacy endpoint
For 0.50mg/40bar device configuration, the reduction in pain was statistically significantly superior to placebo treatment at all time points combined: n=80 p=0.0431
For the 0.50mg/20bar device configuration, the reduction in pain was statistically significant at the 1 minute time point: n=20 p=0.0134
Duration of effect is shown from 1 to 5 minutes
Safety endpoints
Both 0.50mg/40bar and 0.50mg/20bar were very well tolerated
Conclusion
Based on efficacy and tolerability, either device configuration can be taken forward for future studies at the Back of Hand
14
ALGRX 3268 DEVELOPMENT
Total
Protocol Age Group Phase Patients Primary Endpoint Status
Primary Endpoint
Antecubital Fossa Adults 1 272 Safety and Efficacy
Achieved
Primary Endpoint
Back of Hand Adults 1 183 Safety and Efficacy
Achieved
Evaluate Circulating Primary Endpoint
Pharmacokinetics Adults 1 38
Lidocaine Achieved
Primary Endpoint
Antecubital Fossa Children 2 195 Safety and Efficacy
Achieved
Primary Endpoint
Back of Hand Children 2 145 Safety and Efficacy
Achieved
Primary Endpoint
Back of Hand Children 2 306 Safety and Efficacy
Achieved
Antecubital Fossa and Primary Endpoint
Children 3 574 Safety and Efficacy
Back of Hand Achieved
Antecubital Fossa and
Children 3 500 Safety and Efficacy Enrollment Completed
Back of Hand
2,213
15
AGENDA
Terms of merger agreement Product pipeline of combined company ALGRX 3268: positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense
16
PHASE 3’s: 003 AND 004
IDENTICAL PROTOCOLS
Design
U.S. multicenter, randomized, double-blind, placebo-controlled
Number of subjects
500-600 subjects in each study
Population
Pediatric subjects of either gender (ages 3-18)
Objectives
Confirm efficacy, safety and tolerability of ALGRX 3268 vs. placebo administered on back of hand and antecubital fossa
Primary endpoint
Assessment of pain on venipuncture or peripheral venous cannulation performed 1-3 minutes after ALGRX 3268 or placebo in total population (3-18 yrs.) using FACES rating scale
17
PHASE 3 RESULTS (003)
Primary endpoint achieved (p=0.007)
Statistically significantly less pain on needle insertion in treated group compared to placebo group assessed using FACES rating scale
574 patients at six U.S. clinical trial sites
ALGRX 3268 group = 289 patients (ages 3-18)
Placebo = 285 patients (ages 3-18)
No significant safety issues
Well tolerated
18
PROJECTED TIMELINE FOR ALGRX 3268
Clinical
Data from second Phase 3 trial (004) expected within two months
Regulatory
Reviewed as a drug by the FDA Analgesics and Acute Care Division
Registration
File NDA in 1H06
Product approval in 1H07
19
ALGRX 4975 – VR1 ANESTHETIC
Capsaicin Overview
Administered locally at the
site of pain
Single administration may
provide analgesia for
weeks to months
Non-opioid based
Only reduces long-term
noxious pain associated
with C-neurons
Does not affect other
nerve fibers important for
motor skills
Activates the VR1 channel; expressed by pain receptor C-fibers
Blocks noxious pain with long duration
20
ALGRX 4975 DEVELOPMENT
Protocol |
| Phase Total Patients Primary Endpoint Status |
Postsurgical |
| Pain |
Bunion |
| Removal Surgery 2 40 Time to Rescue Medication Primary Endpoint Achieved |
Bunion |
| Removal Surgery 2 182 Magnitude of Pain Relief Primary Endpoint Achieved |
Hernia |
| Repair 2 48 Magnitude and Duration of Pain Relief Ongoing |
Total |
| Knee Replacement 2 60 Dosing Study Ongoing |
Cholecystectomy |
| 2 40 Magnitude of Pain Relief Ongoing |
Neuropathic |
| Pain |
Morton’s |
| Neuroma 2 60 Magnitude and Duration of Pain Relief Ongoing |
Musculoskeletal |
| Pain |
End-Stage |
| Osteoarthritis 1 16 Safety Primary Endpoint Achieved |
End-Stage |
| Osteoarthritis 2 12 Magnitude and Duration of Pain Relief Primary Endpoint Achieved |
Osteoarthritis |
| of the Knee 2 52 Magnitude and Duration of Pain Relief Primary Endpoint Missed |
Tendonitis |
| 2 40 Magnitude and Duration of Pain Relief Achieved 30 Day Endpoint; |
Ongoing
21
ECZEMA: LARGE UNMET NEED
Unmet medical need
Existing therapies are not satisfactory (steroids and calcineurin inhibitors)
Safety issues with long-term application of steroids, especially in children, and black box warning for cancer risk on on calcineurin inhibitors
Strong preclinical data with NF- B Decoy showing effective treatment for eczema Good drug delivery to the dermis and epidermis with simple formulation Validated, accepted clinical endpoints
Shorter time to proof of concept
22
NF-k |
| B DECOY FOR ECZEMA |
Two Phase 1/2 trials underway Clinical data expected in 1Q/06 Adults with mild-moderate eczema Endpoints
Safety, tolerability and PK
Multiple endpoints to assess preliminary efficacy
Physician and patient assessments of target area (signs and symptoms)
US Trial (75 patients)
Four cohorts
0.25% |
| 20 patients |
0.50% |
| 20 patients |
1.00% |
| 20 patients |
Placebo |
| 15 patients |
21 days of treatment and 28 days of follow-up
Ex-US Trial (120 patients)
Three cohorts
1.0% |
| daily 40 patients |
1.0% |
| 2x day 40 patients |
Placebo |
| 40 patients |
28 days of treatment and 14 days of follow-up
23
ALGRX 1207
IND-enabling studies underway
New chemical class of local anesthetic for topical analgesia
Deep, rapid penetration of the skin and long duration of action Addresses a wide variety of procedures including:
Neuropathic pain
Dermatological surgery
Surgical incisions
24
ALGRX 1207
New local anesthetic allowing rapid and complete topical anesthesia without exotic delivery
Percent complete anesthesia
100 80 60 40 20 0
-120 |
| -110 -100 -90 |
Time, minutes
Percent complete anesthesia
100 80 60 40 20 0
-120 -60 0 60 120 180 240 300 360 420
Time, minutes
Lidocaine
ALGRX 1207
Unique non-clinical results in relevant models
25
AGENDA
Terms of merger agreement Product pipeline of combined company ALGRX 3268: positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense
26
PREVALANCE OF PAIN IN SEVEN MAJOR COUNTRIES
PATIENT NUMBERS
Prevalence |
| of post-operative pain 75,068,000 |
Prevalence |
| of back pain 208,996,000 |
Prevalence |
| of HIV and AIDS pain 847,000 |
Prevalence |
| of diabetic neuropathy pain 13,243,000 |
Prevalence |
| of osteoarthritic pain 46,610,000 |
Above indications are all targets of Corgentech pipeline
Source: Datamonitor
27
3268: TOPICAL LOCAL
ANESTHESIA MARKET DYNAMICS
Strong focus of pain management including treatment protocols and guidelines Increase in dedicated pediatric hospitals and specialized pediatric departments in larger general hospitals Continuing pressure on cost reduction and patient through-put in hospitals Fundamental market need for easy to use, fast onset topical local anesthetic
Current market dynamics provide an excellent opportunity for a fast acting, easy to use topical local anesthetic product like ALGRX 3268
28
UNDERSERVED MARKET
Target market
Only 2.1MM out of 18MM venipuncture procedures in children’s hospitals and large academic institutions utilize a topical local anesthetic today
Low utilization of topical local anesthetics (12% of pediatric procedures) due to
slow onset of action
lack of promotion of currently available drugs
Faster onset of action, needleless injection and promotion will allow significant penetration and growth into target market of 18MM pediatric procedures
29
3268: CLINICAL PRACTICE OF TOPICAL LOCAL ANESTHETICS IN HOSPITALS
Many hospitals offer topical local anesthetic agents as an option to reduce venipuncture pain
Existence of established protocols for TLA use is mixed
Nurses rather than physicians usually decision maker
Some ERs apply topical local anesthetics, however use is often impractical due to delayed onset of action Topical local anesthetics are most commonly offered to pediatric patients ages 3-10
Parents and sometimes children over 10 occasionally request topical local anesthetics to reduce venipuncture pain
Patient and parent anxiety levels are key factors driving the use of topical local anesthetics
Previously treated children frequently request topical local anesthetics
30
3268: PHASED MARKETING APPROACH
31
ALGRX 4975: POST-OPERATIVE PAIN MARKET
US post-operative pain market: $1.7 billion Virtually all patients experience some level of pain post operatively
50% indicate lack of adequate pain control
Patients’ post-surgical pain experiences between 1993 and 1999 have not improved
Europe also under treats post-operative pain
Pain in hospital associated with increased length of stay, longer recovery times, poorer patient outcomes
32
ALGRX 4975: HIGH VOLUME SURGERIES
Procedure |
| Volume |
Caesarean |
| Section 1,163,893 |
Hysterectomy |
| (all) 1,042,715 |
Episiotomy |
| 417,699 |
Arthroplasty |
| (knee) 399,139 |
Hip |
| Replacement, 343,554 |
total/partial |
|
CABG |
| 316,471 |
Colorectal |
| resection 280,969 |
33
CURRENT POST-OP PAIN MEDICATIONS VS. ALGRX 4975
Epidurals
Use declining significantly due to contra-indication in combination use with anticoagulants
Opioids
Nausea, vomiting, respiratory depression and constipation
Sedation may limit the ability of the patient to ambulate and prolong time to discharge
Decreased bowel function can lead to an ileus which causes morbidity and prolongs hospitalization
Concern about addiction leads to insufficient pain relief which has physiologic consequences
Non-narcotics
Unacceptable anesthesia for moderate to severe pain
ALGRX 4975
Unlikely to be contra-indicated for use in conjunction with anticoagulants
Site-specific with limited systemic exposure and unlikely to cause nausea, vomiting, respiratory depression or sedation
No addiction potential
Long-acting with single administration and ideal for moderate to severe pain
34
NF-?B DECOY: ECZEMA MARKET
Eczema market is comprised of mild, moderate and severe patient segments within the pediatric and adult patient populations
Patient Population Segmented by Mild, Moderate and Severe (US, EU, Japan)
Severe 10%
5.2M 15.6M 31.1M
Moderate 30%
Mild 60%
Sources:
1. International Consensus Conference on Atopic Dermatitis II: clinical update and current treatment strategies, BJD, 2003; 148 (Suppl. 63): 3-10
2. |
| Prevalence of Atopic Dermatitis in Japanese Adults, Muto T, Hsieh SD et al., BJD, 2003 Jan; 148(1): 117-21 |
35
NF-kB DECOY: Rx SALES (U.S.) $900
$800
(millions)
$700
$600
$500
Dollars
$400
$300
Total
$200 $100 $0
1999 |
| 2000 2001 2002 2003 2004 |
Corticosteroids Protopic Elidel
Source: IMS Health, 2004
36
ALGRX1207: TARGET MARKET
Deep, rapid penetration of the skin Long duration of action Addresses neuropathic pain market Non-exotic delivery
($ in millions) $45 $107 $215 $300 $400
2001 |
| 2002 2003 2004E 2005E (IMS) (IMS) (IMS) (Endo) (Endo) |
37
AGENDA
Terms of merger agreement Product pipeline of combined company ALGRX 3268: Positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense
38
DEAL TIMELINE
Merger requires stockholder approval
Both boards have approved merger
Merger documents to be filed in coming weeks
S-4 and related joint Proxy Statement
Shareholder vote expected to occur in late 2005 / early 2006
39
AGENDA
Terms of merger agreement Product pipeline of combined company ALGRX 3268: positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense
40
WHY THIS MERGER MAKES SENSE
Four product development programs focused on significant clinical problems with attractive market potential
Each drug has unique mechanism of action offering risk diversification
Each drug has potential for approval in multiple indications
Each drug can be commercialized with specialty sales force
All discovery and development programs 100% owned
Phase 3 program ALGRX 3268 for the treatment of venipuncture
Statistically significantly less pain in first Phase 3 trial
Second Phase 3 trial data expected within two months
Expect to file NDA in 1H06
Expect product approval in 1H07
Development and commercial expertise in critical areas
Marketing, commercialization, regulatory affairs, manufacturing and clinical trials management
Financial strength and flexibility
41